Geron Corp (GERN)
Geron Corporation is a biotechnology company focusing on developing innovative therapies for cancer and regenerative medicine. It is known for its work in telomerase inhibition, aiming to treat cancer by targeting the enzyme crucial for cancer cell immortality, and exploring strategies for tissue repair and regenerative therapies.
Company News
Biotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.
Geron Corporation (GERN) is facing a securities fraud lawsuit for allegedly making false and misleading statements about its drug Rytelo's launch and potential growth, leading to investor losses.
Geron, a commercial-stage biotech company, reported its Q1 2023 results, which fell short of analyst expectations. While the company's cancer drug Rytelo generated $39.6 million in sales, it was lower than the $50.5 million analysts had projected. Geron maintained its guidance for operating expenses and cash runway.
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
All three small-cap biotech/biopharma stocks have attractive risk/reward profiles and potential catalysts on the horizon. Click here for the complete stock list.
